Once this is done, the drug will be marketed under the name Belviq.
The anti-obesity drug will then be approved to be sold to adults with (1) a body mass index (BMI) that is greater than 30 (which means one is obese) or with (2) a BMI that is 27 or above (25 to 29.9 means one is overweight) and with a weight-related medical condition such as type 2 diabetes, hypertension (high blood pressure), or high cholesterol.
Belviq is produced by Arena Pharmaceuticals, which is headquartered in San Diego, California.
For more on this story, please read the June 27, 2012 ABC News article "FDA Approves Weight Loss Drug Belviq".
The article quotes Dr. Janet Woodcock, the director of the FDA's Center for Drug Evaluation and Research.
She states, "Obesity threatens the overall well-being of patients and is a major public health concern. The approval of this drug, used responsibly in combination with a healthy diet and lifestyle, provides a treatment option for Americans who are obese or are overweight and have at least one weight-related comorbid condition."
Page two concludes.